Henderson, Nevada, August 13, 2026 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces financial results and a business update for the second quarter of 2026. Volition management will host a conference call tomorrow, August 14 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below.
Cameron Reynolds, President and Group Chief Executive Officer, said:
“We have made strong progress across all of our product pillars throughout 2026 to date.
“We are currently in discussions, including undertaking technology evaluations, with more than a dozen of the world’s leading diagnostic and liquid biopsy companies where our goal is to enter into licensing agreements and other arrangements that will bring revenue in the form of up front milestone payments, royalties and/or other recurring revenue. Discussions are at various stages of the negotiation process across our different pillars with our laser focus on executing further licensing agreements.
“We announced our collaboration with Sysmex Corporation, a global leader in the field of in vitro diagnostics for hemostasis and thrombosis, among other diseases, where Neutrophil Extracellular Traps (“NETS”) play such an important role.
“In May, we announced the submission for peer review of a clinical manuscript reporting the high accuracy of our Nu.Q® Vet feline prototype assay in detecting lymphoma in cats, our third species. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment. The feline test could greatly expand the market of our Nu.Q® Vet platform.
“We are working with our long-term collaborators at the Hospices Civils de Lyon, one of Europe’s leading cancer centers, on the reimbursement submission for Nu.Q® Lung Cancer. Reimbursement is the last step on the path to the first use of Nu.Q® in routine clinical practice, an exciting prospect which is core to Volition’s mission, using our tests to help save lives.
“We continue to add to our significant data rooms with published, submitted and confidential data across our product pillars. Most notably, we recently announced the publication of our first peer-reviewed paper demonstrating our breakthrough Capture-Seq™ liquid biopsy technology.
“The Total Addressable Markets1 (TAMs) for our technologies, on an annualized basis, are multi-billion-dollar opportunities (estimated at more than $27 billion across all of our product pillars), not only for Volition, but for our licensing partners. Volition has made strong progress, both clinically and commercially, and our technology is now poised to be used very widely in a broad range of clinical utilities.“
Financial Highlights
- First half of 2026 revenue was $1.4 million, 112% growth over the first half of 2025
- Revenue for the second quarter of 2026 was approximately $0.4 million, in line with the same period in 2025
- Operating expenses for the second quarter of 2026 were 32% lower than the same quarter in 2025, reflecting the impact of our cost reduction program
- Operating loss was $4.2 million for the second quarter of 2026, down 34% versus the comparable quarter in 2025
- Net cash used in operating activities was $5.2 million for the second quarter of 2026, 18% lower than the same quarter in 2025
- Receipts in the second quarter of 2026 included:
- $1.2 million in net proceeds from equity sales through our at-the-market facility
- $4.1 million in net proceeds from the issuance of shares and warrants in a confidentially marketed public offering
Event: VolitionRx Limited Second Quarter 2026 Earnings and Business Update Conference Call
Date: Friday, August 14, 2026
Time: 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time
U.S. & Canada Dial-in: 1-877-407-9716 (toll free)
U.K. Dial-in: 0 800 756 3429 (toll free)
Toll/International: 1-201-493-6779
Conference ID: 13762190
Louise Batchelor, Group Chief Marketing & Communications Officer of Volition will host the call along with Cameron Reynolds, President and Group Chief Executive Officer and Terig Hughes, Group Chief Financial Officer. The call will provide an update on important events that have taken place in the second quarter of 2026, subsequent events and upcoming milestones.
A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until August 28, 2026. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13762190.
- Data on File, VNRX TAM Model
###
